SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp. is experiencing a massive surge, fueled by escalating geopolitical tensions, a sharp rise in oil prices, and widespread reports of a closed Strait of Hormuz. The community is actively discussing its low float and the potential for a significant short squeeze, anticipating further multi-day gains for the energy stock.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy is actively trending as escalating geopolitical tensions in the Middle East, including disruptions to key energy infrastructure and shipping routes, ignite fervent speculation across the oil and gas sector. The community is buzzing with comparisons to past parabolic runs during global conflicts, debating the stock's potential for a significant squeeze and sustained rally amid heightened volatility.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is a major discussion point as investors await its earnings call for critical updates on satellite deployment and commercialization guidance, following significant new partnerships to expand its direct-to-device connectivity across Europe and Asia. The community remains divided between high conviction in the long-term disruptive technology and concerns over execution and profitability in this capital-intensive sector.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is trending following a significant pre-announcement of Q3 revenue far exceeding guidance and implying massive year-over-year growth, driven by strong demand in AI data center infrastructure. The community is actively debating whether this signals a strong post-earnings rally, especially given soaring hyperscaler CapEx and a new "Buy" rating from Goldman Sachs, or if the stock's recent volatility and prior "sell the news" patterns will persist.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as investors eagerly await its upcoming Fiscal Year 2025 earnings, with the community anticipating strong financial results and a potential short squeeze. Recent news of the company's acquisition of a regulated financial platform for non-dilutive AI infrastructure project financing is also a key talking point, fueling optimism for its long-term growth as an AI infrastructure giant.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is drawing significant attention after achieving an Airworthiness Certificate for its N704AX aircraft, paving the way for piloted VTOL testing, alongside a Starlink partnership and UK defense expansion; this operational progress has sparked a divided community sentiment ahead of its upcoming earnings.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is experiencing a sharp rally following a strong earnings beat and raised full-year guidance, fueled by robust Atlas cloud adoption and significant AI workload growth, prompting analysts to upgrade price targets while some in the community debate its current valuation.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is experiencing extreme volatility and a sharp sell-off following a Raymond James downgrade and news that the US Space Force is re-competing a major contract, sparking intense community debate on whether the market reaction is overdone given robust demand for drone technology.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as CEO Anthony Noto's significant share purchase ignites community optimism, with many viewing it as a strong bullish signal and eagerly anticipating potential S&P 500 inclusion news for the fintech company.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is heavily discussed as it defies escalating geopolitical tensions with Iran and the reported closure of the Strait of Hormuz, showcasing surprising resilience that has frustrated bearish expectations while bulls celebrate the "stonks only go up" phenomenon.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Revenue recognized under the Sanofi agreement, including milestone and royalty payments, amounted to $98 million in Q4.</li><li>The company recorded net income of $18 million during the quarter, compared to an $81 million loss during the year-ago period.</li><li>Selling, general, and administrative expenses fell 53% year-over-year.&nbsp;</li></ul>Novavax, Inc. (NVAX) reported a sharp increase in fourth-quarter (Q4) and 2025 revenue as the vaccine maker leaned on partnership income, cost cuts and product sales.The Maryland-based biotech generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11. Both the metrics surpassed the analysts’ consensus estimates of $90.26 million and a loss of $0.55, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Q4 Performance Highlights</h2>Annual revenue surged 65% YoY to $1.12 billion, driven in large part by $625 million in Nuvaxovid sales linked primarily to settlements of earlier advance purchase deals.Quarterly product sales totaled $39 million, while full-year product sales rose to $685 million. Revenue recognized under the Sanofi agreement, including milestone and royalty payments, amounted to $98 million in Q4 and $386 million for the year. The company said it earned $225 million in milestones from the Sanofi collaboration in 2025.<blockquote>"In 2025, we made significant progress on our corporate strategy, marked with the successful achievement of key milestones under our Sanofi agreement, progress towards potential new partnerships, in the form of multiple MTAs signed with other parties enabling experimentation with our Matrix-M adjuvant technology and the advancement of our own R&amp;D efforts.”-John C. Jacobs, President and CEO, Novavax</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax stock</a> traded over 1% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;&nbsp;<h2 class="st-heading-2">Costs Fall As Profitability Improves</h2>Novavax reduced its cost of sales to $22 million in the fourth quarter from $37 million a year earlier. The decline followed the divestiture of its Czech manufacturing site and lower overhead and inventory-related charges.Selling, general, and administrative expenses fell more than half YoY as commercial responsibilities transitioned to Sanofi and infrastructure was streamlined. The company recorded net income of $18 million in Q4, compared to an $81 million loss during the year-ago period. Novavax ended 2025 with $751 million in cash and equivalents.&nbsp;NVAX stock has gained ovr 0% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-falls-premarket-es8-demand-powers-through-chip-shortage/cZTG3ncRIbK">Nio Stock Falls Premarket: Flagship ES8 Demand Powers Through Fresh Chip Shortage Disruption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue 

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

Equity

<ul class="summary-bullets"><li>PROCEPT BioRobotics’ Q4 revenue of $76.4 million and loss per share of $0.53 both missed street estimates.&nbsp;</li><li>According to Bank of America, in Q4, PROCEPT BioRobotics delivered results that fell short of analyst forecasts by 18.5%.</li><li>The firm indicated that the latest quarterly update failed to ease concerns about execution and financial momentum.</li></ul>Bank of America has downgraded PROCEPT BioRobotics Corp. (PRCT) shares, citing mounting concerns about earnings visibility and profitability, reflecting skepticism about the company’s near-term performance as it navigates widening losses.In the fourth quarter (Q4), the company reported a revenue of $76.4 million, a 12% year-over-year (YoY) increase, and a loss per share (EPS) of $0.53. Both the financial metrics were below the analysts’ consensus estimates of $93.70 million and a loss of $0.31, respectively, according to Fiscal AI data.&nbsp;<a href="https://stocktwits.com/symbol/PRCT">PROCEPT BioRobotics’ stock</a> traded over 28% lower in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">BofA Flags Profitability Concerns</h2>Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’ and slashed its price target to $20 from $38, according to TheFly. The firm flagged fresh doubts following the company’s Q4 earnings discussion, noting uncertainty about whether management can meet Wall Street’s projections.&nbsp;Bank of America indicated that the latest quarterly update failed to ease concerns about execution and financial momentum.According to Bank of America, in Q4, PROCEPT BioRobotics delivered results that fell short of analyst forecasts by 18.5%. The shortfall coincides with a shift in the company’s longstanding approach to offering volume-based discounts to customers. At the same time, management has undertaken a reorganization of its sales team, adding another layer of transition risk.The firm emphasized that the company remains unprofitable, with operating losses deepening after the latest earnings. That trend, Bank of America argued, constrains the stock’s valuation and limits potential upside in the near term.&nbsp;<h2 class="st-heading-2">Retail Traders Remain Bullish Despite Selloff</h2>However, on Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume flipped to ‘extremely high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_26_055954_png_4ab610861f.webp" alt="PRCT’s Sentiment Meter and Message Volume as of 05:30 a.m. ET on Feb. 26, 2026 | Source: Stocktwits" width="933" height="101"><figcaption>PRCT’s Sentiment Meter and Message Volume as of 05:30 a.m. ET on Feb. 26, 2026 | Source: Stocktwits</figcaption></figure>PRCT stock has declined by over 59% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-falls-premarket-es8-demand-powers-through-chip-shortage/cZTG3ncRIbK">Nio Stock Falls Premarket: Flagship ES8 Demand Powers Through Fresh Chip Shortage Disruption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the PROCEPT BioRobotics Corporation logo is seen displayed on a smartphone screen.

PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20

Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’. 

<ul class="summary-bullets"><li>As a result of the delisting decision, CASI’s shares will be suspended for trading at the opening of business on Thursday.</li><li>The company stated that it does not intend to review the Nasdaq’s delisting decision.</li><li>CASI stated in its announcement that it expects the company's existing shares to be traded on the over-the-counter market operated by OTC Markets Group Inc.</li></ul>CASI Pharmaceuticals Inc. (CASI) shares tanked more than 64% in Wednesday’s opening trade after the company announced that it had received a delisting decision from the Nasdaq.CASI stated that the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.As a result of the delisting decision, CASI’s shares will be suspended for trading at the opening of business on Thursday. The company stated that it does not intend to review the Nasdaq’s delisting decision.CASI had received an extension in December 2025 to comply with the Nasdaq’s Market Value of Listed Securities (MVLS) Rule 5550(b)(2) by Feb. 17, 2026.The MVLS rule requires a company’s market capitalization to be above $35 million for 30 consecutive trading days.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CASI">CASI Pharmaceuticals</a> trended in the ‘bullish’ territory.<h2 class="st-heading-2">Where Will CASI’s Existing Shares Be Traded Now?</h2>CASI stated in its announcement that it expects the company's existing shares to be traded on the over-the-counter market operated by OTC Markets Group Inc.However, the company said there is no guarantee that this will materialize.“The delisting from Nasdaq will have no significant impact on the Company's operations,” the company said.<h2 class="st-heading-2">What Does CASI Do?</h2>CASI is a San Francisco, California-based biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for the treatment of organ transplant rejection and autoimmune diseases.In January, CASI announced additional data from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia (ITP). The company stated that CID-103 demonstrated a manageable safety profile, with only two Grade 3 treatment-related events and no dose-limiting toxicities.Grade 3 treatment-related events are severe and medically significant, but not life-threatening adverse events.<a href="https://stocktwits.com/symbol/CASI">CASI stock</a> is down 66% year-to-date and 87% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rxrx-stock-soars-pre-market-on-q4-beat-recursion-reached-inflection-point/cZRy27nR46D">RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low?

CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.

<ul class="summary-bullets"><li>The reverse split will consolidate every 30 existing shares into one new share.</li><li>The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.</li><li>After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million.</li></ul>Incannex Healthcare Inc. (IXHL) announced on Wednesday that its board of directors has approved a 1-for-30 reverse stock split, which was previously approved by shareholders at a special meeting on May 27, 2025.The reverse split is set to take legal effect at 4:01 p.m. ET on Feb. 26, 2026.<h2 class="st-heading-2">Purpose And Impact Of The Split</h2>Following this adjustment, Incannex Healthcare common shares will begin trading on The Nasdaq Capital Market under a new CUSIP number, 45333F 208, on February 27, while retaining the ticker symbol ‘IXHL’.The reverse split will consolidate every 30 existing shares into one new share, aiming to raise the per-share market price. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements and maintain continued listing eligibility.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/IXHL">Incannex stock</a> tumbled over 32% on Wednesday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Share Structure And Equity Adjustments</h2>Incannex said that&nbsp;no fractional shares will be issued, and shareholders entitled to fractional amounts will receive an additional share to round up to a whole unit.&nbsp;After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million, although the total number of authorized shares will remain unchanged. Existing equity awards and stock incentive plans will see proportional adjustments in both share numbers and exercise prices to reflect the split.&nbsp;In January, Incannex said it is entering 2026 with over $70 million in cash, following a $12.5 million private placement financing and the elimination of legacy Series A warrants. The company also authorized a $20 million share repurchase program.IXHL stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q4-earnings-today-retail-says-pressure-is-worse-this-time/cZRy3JBRIG4">Nvidia Q4 Earnings Today – Retail Says 'Pressure Is Worse This Time’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background.

Why Did IXHL Stock Tank Over 32% Today? 

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 


<ul class="summary-bullets"><li>The therapy is to treat adults and children with Friedreich’s ataxia, a progressive neurodegenerative disorder.</li><li>Preliminary findings from the open-label study show that nomlabofusp increased FXN levels in patients’ skin to amounts observed in asymptomatic carriers.&nbsp;</li><li>FDA agreed that skin FXN could serve as a novel surrogate endpoint, supporting the planned Biologics License Application submission.</li></ul>Larimar Therapeutics, Inc. (LRMR) announced on Tuesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its frataxin (FXN) protein replacement therapy, nomlabofusp.&nbsp;The therapy is to treat adults and children with Friedreich’s ataxia (FA), a progressive neurodegenerative disorder causing nervous system damage.<h2 class="st-heading-2">FDA Endorses Skin FXN As Surrogate Endpoint</h2>The FDA’s decision follows encouraging clinical data from Larimar’s ongoing open-label study and a recent Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program meeting.&nbsp;The agency also agreed that skin FXN could serve as a novel surrogate endpoint reasonably likely to predict clinical benefit, supporting the planned Biologics License Application (BLA) submission targeted for June 2026. The FDA additionally confirmed that the planned analyses, reference population, and clinical endpoints are aligned with BLA requirements.Following the FDA’s decision,&nbsp;<a href="https://stocktwits.com/symbol/LRMR">Larimar stock</a> traded over 30% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_24_084542_png_18caaedccf.webp" alt="LRMR’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>LRMR’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Encouraging Clinical Data</h2>Preliminary findings from the open-label study show that nomlabofusp increased FXN levels in patients’ skin to amounts observed in asymptomatic carriers.&nbsp;Improvements were seen across four key clinical measures, the modified Friedreich Ataxia Rating Scale (mFARS), FARS-Activities of Daily Living (ADL), 9-Hole Peg Test (9-HPT), and Modified Fatigue Impact Scale (MFIS) after one year of treatment.&nbsp;The results suggest that nomlabofusp could slow or reverse FA progression compared with the natural disease course observed in the Friedrich’s Ataxia Clinical Outcomes Measure Study (FACOMS).LRMR stock declined by over 7% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intuit-stock-rallies-pre-market-today-anthropic-connection/cZRvyjtR4C7">Intuit Stock Rallies Pre-Market Today And There’s An Anthropic Connection</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? 

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.

<ul class="summary-bullets"><li>McCutcheon said findings presented for VIR-5500 surpassed expectations and strengthened Vir’s standing among therapies in prostate cancer.</li><li>He noted that the results bolster confidence in Vir’s PRO-XTEN platform and add support to the company’s outlook for its hepatitis D regimen.</li><li>Morgan Stanley analyst Michael Ulz increased his price target on Vir to $24 from $20.</li></ul>Vir Biotechnology Inc. (VIR) received a pair of bullish calls from Wall Street after unveiling fresh clinical data and a sizable new drug partnership, prompting analysts to raise their ratings and price targets on the stock.On Monday, the company reported strong fourth-quarter earnings and encouraging Phase 1 results for its cancer therapy study.&nbsp;<h2 class="st-heading-2">Raymond James Upgrades Vir Biotechnology</h2>Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12 following the series of corporate updates, according to TheFly.&nbsp;According to McCutcheon, findings presented for VIR-5500 surpassed expectations and strengthened its standing among PSMA-directed T-cell engager therapies in prostate cancer.He noted that the results bolster confidence in Vir’s PRO-XTEN platform and add support to the company’s outlook for its hepatitis D regimen combining tobevibart and elebsiran, which he believes has a viable regulatory path.<a href="https://stocktwits.com/symbol/VIR">Vir Biotechnology stock</a> traded over 60% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_24_071715_png_bf610d177d.webp" alt="VIR’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits" width="926" height="103"><figcaption>VIR’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure>Separately, Morgan Stanley analyst Michael Ulz increased his price target on Vir to $24 from $20 while maintaining an ‘Overweight’ rating. Ulz said early-stage data for VIR-5500 reinforce its potential to emerge as a leading treatment option in prostate cancer.<h2 class="st-heading-2">New Partnership Adds Financial Backing</h2>Vir also announced a collaboration with Astellas Pharma that includes $335 million in upfront and near-term payments. The agreement outlines a 50/50 profit split in the U.S. and royalty payments on sales outside the country, providing additional capital and shared commercialization support.The partnership will co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues.&nbsp;Vir is eligible to earn up to $1.37 billion in additional development, regulatory, and sales milestones.VIR stock has declined by over 21% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-is-bringing-mac-mini-production-to-texas-now/cZRvveYR4zD">Apple Is Bringing Mac Mini Production To Texas Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Vir Biotechnology logo is seen on a smartphone and a computer screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

<ul class="summary-bullets"><li>Investigators noted that tumor shrinkage deepened over time, mirroring patterns previously observed with lifileucel in melanoma.</li><li>The data comes from a clinical trial testing lifileucel in patients with advanced undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS).</li><li>The company plans to consult with the U.S. Food and Drug Administration regarding a potential expedited review process.</li></ul>Iovance Biotherapeutics Inc. (IOVA) on Tuesday reported encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel, in patients with aggressive soft tissue sarcomas who had exhausted prior treatments.&nbsp;The company said the findings support plans to pursue a potential speedy approval pathway in the United States.<h2 class="st-heading-2">Early Trial Results Show Strong Responses</h2>The data comes from a clinical trial led by Memorial Sloan Kettering Cancer Center and backed by Iovance, testing lifileucel in patients with advanced undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) whose disease had progressed after at least one systemic therapy.Among the first six patients whose outcomes could be evaluated, half experienced a confirmed tumor response. Investigators noted that tumor shrinkage deepened over time, mirroring patterns previously observed with lifileucel in melanoma and other solid tumors.&nbsp;The company also reported strong fourth-quarter (Q4) earnings led by $65 million in&nbsp; Amtagvi revenue. Following the update,&nbsp;<a href="https://stocktwits.com/symbol/IOVA">Iovance stock</a> traded over 5% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock shifted to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Next Steps Toward Registration</h2>Based on the initial findings, Iovance said it intends to launch a single-arm registrational trial in the second quarter of 2026 for second-line advanced UPS and DDLPS. The company plans to consult with the U.S. Food and Drug Administration regarding a potential expedited review process.<blockquote>“In the first clinical trial of a TIL cell therapy in UPS and DDLPS, one-time treatment with lifileucel demonstrated compelling and unprecedented response rates with the potential to address a significant unmet need in patients who are refractory to frontline standard of care.”-Lauren Baker Banks, Sarcoma Medical Oncologist, Memorial Sloan Kettering Cancer Center</blockquote>In Q4, total product revenue was about $87 million, marking roughly 30% growth year-over-year. Gross margin for the quarter was approximately 50%, driven by improved operations and ongoing cost control efforts.IOVA stock has declined by over 47% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/vir-stock-surges-pre-market-today-analysts-cheer-strong-cancer-data-astellas-partnership/cZRvUqdR4C5">VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Iovance Biotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did IOVA Stock Gain Pre-Market Today? 

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings. 

<ul class="summary-bullets"><li>Canaccord also lowered its price objective, cutting it to $80 from $105, while keeping a ‘Buy’ rating in place.</li><li>Analyst Catherine Ramsey Schulte said Baird updated its financial model to reflect the trial outcome but did not downgrade the stock.</li><li>Canaccord said it continues to view the broader data set from the U.K. initiative constructively.</li></ul>Grail Inc. (GRAL) stock remains in the spotlight after two Wall Street firms trimmed their price targets following disappointing data from a key U.K. study, even as both maintained bullish ratings.On Thursday, the company announced that its study of the Galleri blood test, used for yearly multi-cancer screening in England’s National Health Service, failed to achieve its main goal.<a href="https://stocktwits.com/symbol/GRAL">Grail stock</a> traded over 42% lower in Friday’s premarket. However, on Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_20_072336_png_b625b032ea.webp" alt="GRAL’s Sentiment Meter and Message Volume as of 07:00 a.m. ET on Feb. 20, 2026 | Source: Stocktwits" width="933" height="104"></figure><h2 class="st-heading-2">Target Cuts Follow Trial Update</h2>The outcome prompted analysts to revisit their financial assumptions and adjust expectations for the blood-based cancer screening test developer. Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating, according to TheFly.&nbsp;Canaccord also lowered its price objective, cutting it to $80 from $105, while keeping a ‘Buy’ rating in place.<h2 class="st-heading-2">Canaccord Sees Market Overreaction</h2>Schulte said Baird updated its financial model to reflect the trial outcome but stopped short of downgrading the stock, signaling continued confidence in Grail’s long-term commercial prospects despite the setback.Canaccord acknowledged disappointment over the topline findings from the NHS-Galleri study and conceded that the regulatory and commercial path ahead may now appear less predictable.Still, the firm said that the steep after-hours drop, which approached 50%, is an ‘overreaction’. Canaccord said it continues to view the broader data set from the U.K. initiative constructively, even though the study did not achieve its principal goal.GRAL stock has gained over 112% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-kosmos-energy-stock-surge-pre-market-today/cZRNcfoR4xe">Why Did Kosmos Energy Stock Surge 10% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The NYSE app is seen in the app store in this illustration photo taken in Warsaw, Poland.

Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone

Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating.

Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)?

<ul class="summary-bullets"><li>After the adjustment, Intensity Therapeutics stock will begin trading on February 19, retaining the ticker symbol INTS.</li><li>The stock consolidation will reduce the total shares outstanding from approximately 63.3 million to about 2.53 million.</li><li>In January, the company said it raised more than $20 million in 2025, extending its cash runway into the second quarter of 2027.&nbsp;</li></ul>Intensity Therapeutics, Inc. (INTS) on Friday announced a 1-for-25 reverse stock split approved by its board and shareholders, aiming to boost the per-share price of its common stock to meet Nasdaq’s minimum listing requirements.The reverse split, scheduled to take effect at 4:01 p.m. ET on February 18, will consolidate every 25 existing shares into a single new share.<h2 class="st-heading-2">Changes After The Reverse Split</h2>After the adjustment, Intensity Therapeutics stock will begin trading on February 19, under a new CUSIP number 45828J 202 while retaining the ticker symbol INTS.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/INTS">Intensity Therapeutics stock&nbsp;</a>traded 25% lower on Friday morning.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;Intensity is a late-stage biotech company developing its own cancer treatments. It uses a special drug-linking technology to create therapies that aim to destroy tumors and help the immune system better detect cancer.<h2 class="st-heading-2">Impact on Shareholders</h2>The stock consolidation will reduce the total shares outstanding from approximately 63.3 million to about 2.53 million. No fractional shares will be issued; instead, shareholders entitled to a fraction will receive cash payments based on the adjusted closing price on February 18.Alongside the split, the company will make proportional changes to stock options, warrants, convertible securities, and shares issued under its stock incentive programs. The total number of authorized shares will remain unchanged.In January, the company outlined its 2025 achievements and mapped out priorities for 2026 as it advances INT230-6, its lead cancer therapy designed to destroy tumors and stimulate immune response. Intensity raised more than $20 million in 2025, extending its cash runway into the second quarter of 2027.&nbsp;INTS stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-slips-premarket-ev-headwinds-mount-wall-street-sees-upside-physical-ai-future/cZR5NHfR4sm">Tesla Stock Slips Premarket As EV Headwinds Mount — But One Wall Street Firm Sees Over 30% Upside On A ‘Physical AI’ Future</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Why Did INTS Stock Plummet 25% Today? 

Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.

SSgA Active Trust - State Street Health Care Select Sector SPDR ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

XLV
Health Care Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Latest XLV News

XLVHealth Care Select Sector SPDR Fund